Gossamer Lung Disease Drug Misses Main Goal in Big Trial – But Shows Real Hope for Sickest Patients
Gossamer Bio’s seralutinib narrowly missed its Phase 3 target for pulmonary arterial hypertension, yet delivered strong benefits in higher-risk patients. Company still plans FDA talks.